GSK to Buy 35Pharma for $950 Million to Broaden Cardiopulmonary and Obesity-Linked Pipeline
GSK has agreed to acquire Canada-based 35Pharma for $950 million, incorporating a cardiopulmonary drug candidate, HS235, into its pipeline. The acquisition is described by the companies as complementary to GSK's push into conditions associated with obesity and is one of several deals pursued under CEO Luke Miels to bolster the company’s drug portfo…